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containing culture medium. In conclusion,
rhKGF does not affect keratinocyte survival after
irradiation, but stimulates proliferation of
surviving cells.
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Purpose: evaluation acute tolerance ot
combined treatment (XRT and HT).
Material/methods: Between April 1999 and
September 2000, 22 patients with prostate
cancer (T1-T3NXMO) were treated with 3D-CRT
and HT. Median age of patients was 68
years.EBRT was administered daily traction of
1.8Gy,total dose 70.2Gy. Planning target
volume (PTV) was defined as c1inical target
volume CTV(prostate and seminal vesicles) with
10mm margins around prostate except posterior
margin where 5mm were used to decrease risk
ot rectum morbidity.Acute toxicities were
evaluated using RTOG scoring scale. Median
follow-up was 11 months. Results: Acute etfects
in gastrointestinal tract (Gl) noted were; rectal
discomfort and mild diarrhea. Acute
genitourinary (GU) symptoms included urgency,
nocturia and dysuria. Gl toxicity was observed in
75 % of patients (grade O and 1), and 25% of
patients (grade 2). GU toxicities were as tollow:
grade Oand 1 -80% ot patients) and grade 2 -
(20% ot patients). No grade 3 ar 4 Gl and GU
toxicities were observed. Conclusions:
Preliminary results of treatment with 3D-CRT
suggested that such modality is well tolerated.
HT did not exacerbate radiation toxicity.
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Number of gene therapy clinical triais and
patients enrolled increases exponentially. Today
there are more than 400 triais and over 4000
patients involved all over the world. However,
most of the trails are in the early clinical phases.
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About 67% of triais are related to cancer. Most
ot the cancer gene therapy strategies are based
on various forms of gene-immunotherapy which
include genetically modified tumor vaccines
(GMTV), direct intratumoral administration of
genes encoding immunostimulatory factors or
insertion of these genes into tumor infiltrating
Iymphocytes (TIL). Other strategies include
suicide gene therapy, direct intratumoral
administration ot genes encoding anti-
oncogenes, gene anti-angiogenic therapy or
bone marrow cells protection against high dose
anti-cancer chemotherapy using MDR genes.
Various gene carries are employed in above
strategies. Retroviral vectors or
Adenoassociated virus vectors are used for
GMTV construction, TIL and bone marrow cells
modifications. Adenoviral vectors and liposomes
are employed tor direct intratumoral gene
administration. Other carriers such as lentiviral
vectors (based on HIV) or SV40 based vectors
are in the preclinical studies.
In January 1996 we have initiated melanoma
gene-immunotherapy clinical trial using GMTV
comprising ot irradiated autologous melanoma
ceUs admixed with ceUs of two allogeneic
melanoma celi lines modified to secrete
interleukin 6 (IL-6) and agonistic soluble IL-6
receptor (sIL-6R). Until now more than 180
patients were enrolled into study. Phase I trail
demonstrated that GMTV is not toxic and
possesses therapeutic potential. Phase II trial
has shown that in melanoma stage IV with
measurable metastatic disease GMTV
significantly extended patients' survival. In 16
out of 45 patients (36%) response to the GMTV
was observed (4 CR, 4 PR and 8 mixed
responses including SD). More than 60% ot
responding patients survived 2 years while none
'ot non-responders survived that period (rank-Iog
test p<O.0001). CD4+/CD8+ T cells ratio,
antibody response, soft tissue metastases and
performance status correlated with c1inical
response. Above results allowed the design ot
the phase III randomized double blind study
which is about to be initiated.
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